Julia Camps Herrero
• Presently Head of the Radiology Department in Hospital de la Ribera since november 2006.
• Initially trained as an abdominal radiologist, I am now fully dedicated to breast radiology since 1999 in a multimodality approach. Under my supervision, the Diagnostic Breast Imaging of La Ribera Hospital has been the first place in the Valencian Community to set up MRI of the breast, MR-guided biopsies, Vacuum-assisted Biopsy guided by ultrasound, Tomosynthesis and Tomo-guided biopsies and presurgical localizations.
Scientific appointments
• Member of the following Scientific Breast Subcomittees European Congress of Radiology (ECR) 2010 and 2011 and of the Programme Planning Committee for 2015 and 2016
• Chairman of the
a.Breast Scientific Subcomittee in ECR 2012.
b.Scientific Committee for the multidisciplinary Meeting Congreso Español de la Mama 2015 (Spanish Senology Congress)
• Current Breast Section Editor for EURORAD
• Peer-Reviewer for the following journals European Radiology, Radiología, Revista de Senología y Patología Mamaria, Diagnostic and Interventional Radiology, Acta Radiologica, Insights into Imaging.
• Invited Speaker at ECR and EUSOBI since 2008, at the Spanish and South American Breast Radiology Meetings since 2008 and meetings by multidisciplinary breast societies (SESPM and GEICAM) since 2005.
• EUSOBI (European Society of Breast Imaging) Vice-President since September 2015

Dr. Felipe A. Calvo obtained his initial medical degree at the Autónoma University of Madrid (1978), finished his residency in Radiation Oncology (Director, Dr. Jose Otero) at the University Hospital Puerta de Hierro (Madrid), and complemented his post-graduate education as fellow at the Radiotherapy Unit (Director, Prof. Michael J. Peckham) of the Royal Marsden Hospital (London) and in the Department of Radiation Oncology and Nuclear Medicine (Director, Prof. Luther W. Brady) at Hahnemann University (Philadelphia). In 1984 he joined the medical staff at the University Clinic of Navarra (Pamplona) as the responsible for Radiotherapy (designated Vice-Chairman of the Department of Oncology in 1987). In 1991 he took over an academic position as Full Professor in the Department of Radiation Oncology and Nuclear Medicine at Hahnemann University, where he developed the IORT project and was, in addition, the Residency Training Program Director. He was selected Chairman of the Department of Oncology at the General University Hospital Gregorio Marañón (Madrid, Spain) in 1993, his serving position at present, which implies the coordination of an integrated Cancer Center in the context of a large University Hospital. In 1995 he was promoted to Full Professor (tenure track) in Radiation Oncology at the Complutense University of Madrid (Spain), where, since 2006 he is Hospital Vice-Dean of the Medical School. In 2007 he obtained a permanent position as university-vinculated Chair-Professor.

Dr. Calvo has been Vice-President of the Spanish Association of Radiotherapy and Oncology, President of the Spanish Commission of Radiation Oncology and Founding President of the International Society of Intraoperative Radiation Therapy. His professional profile is of a clinical oncologist interested in therapeutic development in the field of multidisciplinary oncology, in particular the areas of precise radiotherapy, intraoperative radiotherapy, chemo-radiation, and assessment of tumor response. Is the author (10) and co-editor (15) of scientific textbooks and has authored and co-authored book chapters (73), scientific journal articles (>200) and congress abstracts (>325). The cumulative bibliometric impact factor of his scientific publications reached >300 in 2015. He participated in the editorial board of the International Journal of Radiation Oncology Biology and Physics, Radiotherapy and Oncology and Clinical & Translational Oncology.
In 2010 has published as coordinating editor a comprehensive text book fully written in Spanish on ”Radiation Oncology: Principles, Methods, Management and Clinical Practice”. In 2011 the second edition of “Intraoperative Irradiation. Techniques and Results” under his co-editing responsibility with Dr. Leonard L. Gunderson, Dr. Christopher G. Willett and Dr. Louis B. Harrison. Since 2014 is member of the Scientific Committee of the European School of Oncology.

Prof. Arlene Chan graduated from the medical school of University of Melbourne, Australia and obtained her Fellowship in Medical Oncology from the Royal Australasian College of Physicians and a Masters of Medicine in Palliative Care from the University of Melbourne.
She received a fellowship in breast cancer/cancer genetics from Princess Margaret Hospital, Toronto before returning to Australia as a Consultant Medical Oncologist at Royal Perth Hospital. She has been a breast cancer-specific oncologist at the Mount Hospital since 1999. She is a professor at the Curtin Health Innovation Research Institute, Curtin University and the Director of the breast clinical trials unit at the Mount Hospital. She is a founding member of the Breast Cancer Research Centre – WA (a clinician driven, not-for-profit charitable breast cancer research group based in Perth) and serves as the Vice-Chair. She is a member of the academic steering committee of several breast cancer trials, has been an invited speaker to more than 130 national and international meetings on breast cancer and has authored more than 100 publications. Her interests include clinical research in understanding biological determinants of therapeutic response, optimizing symptomatic care in early and advanced breast cancer and developing data collection systems for clinical research and measuring patient outcomes.

Sanjoy Chatterjee works as a senior consultant clinical oncologist at Tata Medical Center, Kolkata, India, his team seeing around 700 new breast cancer cases every year. Having trained as a clinical oncologist in the UK, Dr Chatterjee was a consultant clinical oncologist treating breast cancer at Newcastle upon Tyne, UK. Dr Chatterjee is currently a PI in studies testing radiation fractionations in breast cancer and co-investigator in sponsored international Phase III studies in targeted therapy in breast cancer.

Prof. Louis Chow is Medical Director of UNIMED Medical Institute in Hong Kong, Executive Director of the Organisation for Oncology and Translational Research in Hong Kong, Distinguished Professor of Macau Science Technology, Honorary Professor of Third Military Medical University, Honorary Professor of Ningxia Medical College School of Clinical Medicine in Ningxia, China, Honorary Professor at Tohoku University in Sendai, Japan, Visiting Professor, Wuhan University of Science and Technology and Honorary Consultant of Kiang Wu Hospital in Macau. Professor Chow was the immediate past Honorary Clinical Professor of Clinical Trials Centre at The University of Hong Kong, past President of the Asian Breast Cancer Society, and former Honorary Secretary, The Hong Kong Academy of Medicine.

Pierfranco Conte is Full Professor of Oncology and Director of the Post Doctoral Fellowship Programme in Medical Oncology at the University of Padova. Prof. Conte is Chief of the Division of Medical Oncology 2 at the Padua Istituto Oncologico Veneto and Coordinator of the Veneto Oncology Network which includes 26 Medical Oncology Divisions in Veneto Region. He specializations include Clinical Oncology, Clinical Immunology and Hematology.
Throughout his career, Prof. Conte has been involved in the development of new regimens for the treatment of solid tumors, with special emphasis on breast and ovarian cancer. He has been Principal Investigator of numerous research projects supported by the National Research Council (CNR), the Italian Association for Cancer Research (AIRC), the Ministry of Health and the Ministry of Education and Research. He has published more than 400 papers in peer-reviewed journals. Main areas of interest are the biological characterization of breast and ovarian cancer and the development of clinical trials in these disorders.
Prof Conte is the recipient of the 2007 Claude Jacquillat Award for Achievement in Clinical Oncology and was awarded the “Stelle della Fenice nel Mondo” prize for scientific excellence in 2014.

Dr. Javier Cortes received a degree in Medicine and Surgery from the Universidad Autónoma de Madrid in 1996. He continued his studies at the University of Navarra, specialising in Medical Oncology at the Clínica Universitaria de Navarra, where he continued as Assistant in the Department of Oncology from 2002. He was Associated Professor of Oncology in the Faculty of Medicine at the University of Navarra during that period. Dr. Cortés was awarded the title of Doctor in Medical Oncology from the University of Navarra in 2002. Since 2003, he has worked in the Department of Medical Oncology at the Hospital Vall d’ Hebron, Barcelona, where he is Coordinator of the Teaching and Training Programme for Residents in Oncology and Senior Specialist in the Area of Breast Cancer with a special interest in New Drugs Development. Dr. Cortés is Head of the Breast Cancer Unit and the Melanoma Unit.
In addition, he has two masters’ degree: “Medical Direction and Clinical Management” by the Universidad Nacional de Educación a Distancia (UNED) and “Research methodology in Health Sciences” by the Universidad Autonoma de Barcelona and a degree in “Statistics in Health Sciences” by the Universidad Autonoma de Barcelona.
Dr. Cortes is the author of more than 100 publications, especially about breast tumours and new drugs and more than 250 communications at different conferences. He actively participates in the development of numerous national and international clinical investigations, especially in relation to drugs directed against molecular targets and new chemotherapy agents, and he is an ad hoc reviewer of various oncology journals.
Dr Cortés is an active member of the Spanish, European, and American Societies of Medical Oncology (SEOM, ESMO, ASCO), a member of the Scientific Committee of the European Society of Medical Oncology and the Scientific Committee of SOLTI group.

Giuseppe Curigliano, MD, PhD is the Chair of the Division of Experimental Therapeutics at European Institute of Oncology, in Milan, Italy, where besides his clinical work, he is a clinician and researcher specializing in early drug development for patients with breast cancer. Dr. Curigliano’s research experiences include principle or coinvestigator in several phase I-II clinical trials with biological, cytotoxic and immune-modulator agents in breast cancer and solid tumors.

Dr. Richard De Boer completed his basic medical and oncology training at the Royal Melbourne Hospital and then in 1997 undertook a 3-year breast and lung cancer clinical research fellowship at the Royal Marsden Hospital in London, working with Professor Ian Smith.
He returned to Melbourne in 2000 and since then has been a consultant medical oncologist working in both public and private practice. His primary areas of clinical interest are in breast and lung cancer, with breast cancer interests focusing on endocrine therapy and mechanisms of resistance, treatment-induced bone loss and bone metastases, and biological predictors of response/survival. He is actively involved in clinical research, and is a member of the Australian New Zealand Breast Cancer Trials Group, and head of the Breast Trials group of Cancer Trials Australia. He has authored or co-authored articles appearing in journals such as the Journal of Clinical Oncology, Annals of Oncology, The Breast and British Journal of Cancer.

Prof. Carsten Denkert is working as full professor of pathology and head of the translational cancer research group at the Institute of Pathology, Charité University Hospital in Berlin, Germany. His main research interest is the evaluation of molecular biomarkers and new technologies in molecular pathology, including tumor-infiltrating lymphocytes and other immune markers. As the group pathologist of the German Breast Group (GBG), he has experience in planning of clinical multicenter studies, central pathology review, tissue banking and tissue-based translational research.

Professor David Dodwell is a Consultant in Clinical Oncology at The Institute of Oncology, St James Hospital , Leeds, UK. He also has a Visiting Professorship to Sheffield Hallam University and works as a senior research fellow within the Early breast Cancer Triallists Collaborative Group (EBCTCG). He has a special interest in the management of breast cancer.
He is a member of several professional organisations including the Royal College of Physicians, the British Medical Association, the British Oncological Association, the Association of Cancer Physicians and the British Breast Group.
Professor Dodwell’s research interests include adjuvant cytotoxic, endocrine and radio therapeutic interventions in breast cancer and the impact of loco regional therapy on mortality. He is chair of the Chemotherapy Clinical information Group for the systemic chemotherapy database (SACT).

Dr. Peter Dubsky was born in Vienna and was schooled in Germany, London and New York City. He received his MD from the University of Vienna in 1997 and began his surgical training at the University Clinic. He completed a post-doctoral fellowship in cancer immunology (Baylor Institute for Immunology Research, Dallas, Texas, USA) between 2002 and 2004. After board certification in General Surgery in 2005, he focused his work on surgical oncology and was promoted to Senior Consultant at the Medical University of Vienna in 2007. He is currently associate Professor with a clinical and scientific focus on breast cancer.
At the Medical University of Vienna (MUV) Dr. Dubsky joined the Vienna Breast Health Care Center Executive Committee and he is coordinator of the multidisciplinary breast cancer tumor board. On a national level he is member of the certification commission that reviews Austria’s breast cancer centers. Furthermore, he has been elected to the Austrian Breast and Colorectal Cancer Study Group (ABCSG) Presidium. He will be leaving MUV on a sabbatical starting in April 2016 to build a breast cancer center at the Hirslanden St. Anna Klinik in Lucerne, Switzerland.
Dr. Dubsky has authored or co-authored more than 100 scientific publications with a total citation count of over 3500 and h-index 29. His lectures have taken him to many European countries, Canada and the USA but also to Jemen, Saudi Arabia, China, Taiwan, Thailand and South Korea. Since 2015 he has joined the faculty of the St. Gallen International Breast Cancer Conference and will join both the St. Gallen board of panelists and the consensus writing committee in 2017.

Laura Esserman

Education

1977 AB, Harvard University, Cambridge, MA
1983 MD, Stanford University, School of Medicine, Stanford, CA
1993 MBA, Stanford University, School of Business, Stanford, CA

Training
1983-85 Resident in General Surgery Stanford University School of Medicine, Stanford, CA
1985-88 Postdoctoral Fellow, Department of Medicine, Division of Oncology Stanford University School of Medicine, Stanford, CA
1988-90 Resident, General Surgery Stanford University School of Medicine, Stanford, CA
1990-91 Chief Resident, General Surgery, Stanford University School of Medicine, Stanford, CA

Licenses and Certifications
04/92 Board Certification, General Surgery
State of California, G 053346
State of Hawaii, 6864

Positions

UCSF Appointments

Current Appointment:

Professor of Surgery and Radiology
Director, UCSF Carol Franc Buck Breast Care Center
Affiliate Faculty Appointments: Institute for Health Policy Studies, Biomedical Informatics, QB3 Clinical Associate

Dame Lesley Fallowfield is Professor of Psycho-oncology at Brighton & Sussex Medical School, University of Sussex where she is Director of the Sussex Health Outcomes Research & Education in Cancer (SHORE-C) group. Her research interests include the measurement of quality of life in clinical trials of cancer therapy and the training of communication skills for health care professionals in cancer. She has published over 350 papers, many book chapters and 3 text books. She lectures and runs training workshops throughout the world in psychosocial oncology, quality of life assessment and communication skills.

Dr. Daniele Generali completed a degree in medicine and surgery from the University of Brescia (Italy) and went on to undertake a specialist Diploma training in Medical Oncology at the University of Turin (Italy). He then obtained a Master’s degree in Molecular Oncology from the University of Turin (Italy) and a DPhil in Molecular Oncology from the University of Oxford (United Kingdom). After his post doctorial training he joined the Azienda Istituti Ospitalieri di Cremona as Head of Laboratory of Molecular Medicine that focused on molecular oncology and is now a Consultant in the Medical Oncology at the Mammary Pathology Unit. From the 2016 he is Professor in Medical Oncology at University of Trieste and he has an hononary contract in Molecular Oncology at University of Oxford
Dr Daniele Generali has been a speaker at numerous regional and global meetings and has authored over 100 scientific papers and 2 scientific books.
He is a member of a number of organizations including: Italian Association of Medical Oncology (AIOM) – American Society of Clinical Oncology (ASCO) – American Society of Cancer Research (ACCR) – European Society of Medical Oncology (ESMO) – European Organisation for Research and Treatment of Cancer (EORTC).

Dr. Michael Gnant is Professor of Surgery and Director of the Department of Surgery at the Medical University of Vienna, Austria, where he also serves as President of the Austrian Breast and Colorectal Cancer Study Group.
His medical career began in 1988 when he graduated in medicine in Vienna after studying in Vienna and Munich. He then specialized in surgery (1994) and surgical oncology. In 1997 and 1998 he worked as a Visiting Scientist at the National Cancer Institute, NIH, Bethesda, USA. In 2004, he became Full Professor at the Medical University of Vienna, where he also heads the Breast Health Center. In 2005, he was elected President of the Austrian Breast & Colorectal Cancer Study Group (ABCSG). Since 2014, he serves as Chairman and Director of the Department of Surgery at Medical University, where he also was elected President of the University’s Senate.
Professor Gnant has published more than 400 original papers in peer-reviewed journals, including 97 as first author, and 113 as senior/corresponding author. His cumulative impact factor is more than 2.800, with >12.000 citations, an average citation index of 32, and an h-index of 45. He has has given numerous lectures at national and international meetings, including Plenary and Highlight Lectures at ASCO (2005, 2014, 2015), EBCC (2010, 2012, 2014, 2016), and SABCS (2013). In addition, he has been the recipient of multiple national and international awards.
He co-leads the Comprehensive Cancer Center Vienna and serves on the famous St. Gallen Consensus Panel for Early Breast Cancer since 2007 (Co-chairing the event after it has moved to Vienna in 2015). He was elected to the European Academy of Science and Arts in 2009. Among other honors, he is a Fellow of the American College of Surgeons.
Dr. Gnant’s research interests include several fields of surgical oncology, in particular breast, colorectal and pancreatic cancer, immunotherapy using antibodies, vaccination with dendritic cells, endocrine intervention, dormant tumor cells, the use of bone targeted treatments in order to silence tumor micrometastases and prevent osteoporosis, and pathway directed therapies such as mTOR and CDK 4/6 inhibition. He has been the Principal Investigator of more than 30 clinical trials, and currently global Co-Chair of the adjuvant PALLAS study.
He is involved in many scientific societies, including the American Society of Clinical Oncology, American Association of Cancer Research, ACS, Breast International Group, EUSOMA, and the European Society of Surgical Oncology. Among other activities, he currently serves as an Executive Board member of B.I.G. and for the Center of Excellence for Clinical and Experimental Oncology in Vienna, independent Reviewer and IDMC member for the European Organization for Research and Treatment of Cancer, the UICC, the German Cancer League, and other international bodies, and Scientific Reviewer and Process Evaluator for the European Union. He has been a member and assessor of the ethical committee of the Vienna Medical University since 2000.
In addition to these responsibilities, he serves as Editor-in-Chief as well as on editorial boards for several journals and serves as reviewer for many peer-reviewed journals, including The Lancet, The New England Journal of Medicine, Journal of the National Cancer Institute, JAMA, Clinical Cancer Research, International Journal of Cancer, The Lancet Oncology, Journal of Clinical Oncology, Breast Cancer Research and Treatment, Annals of Oncology, and many others.

Amit Goyal is a Consultant Oncoplastic Breast Surgeon & Associate Professor at the Royal Derby Hospital, UK
His special interests are oncoplastic & reconstruction surgery, 3D imaging, sentinel node biopsy, breast pain and breast cancer. He is the Breast Cancer Research lead for East Midlands. His research as a part of the ALMANAC trial and NEW START, has helped to further understand and refine the sentinel node biopsy technique. He is the Chief Investigator of the UK-ANZ POSNOC trial. He is the Oncology Specialty Editor of the Surgery journal. His recent research has centered on the development of low cost 3D surface scanning system using gaming technology (Xbox Kinect) for breast reconstruction and cosmetic surgery.
His surgical practice is focussed mainly on oncoplastic and reconstruction surgery and regularly hosts international fellows for oncoplastic & cosmetic breast surgery training.

Katy Hogben
Qualified from London in 1993 and have been a consultant Oncoplastic Breast Surgeon at Imperial College Healthcare for 10 years.
I work in a busy teaching hospital in London which treats over 500 Breast cancers a year. I am lead for the West of London Breast Screening Service. I am very involved in both undergraduate and post graduate training and am training Programme director for West London Higher Surgical Training, General Surgery.
I have been meeting secretary and a trustee for the Association of Breast Surgery (UK) for 3 years.

Prof. Kieran Horgan is a breast surgeon and Associate Professor at the University of Leeds in the UK. He has considerable experience in the management of all aspects of breast surgery and breast cancer care with more than a 100 peer reviewed publications. He was the initiator of the UK Breast Oncoplastic Training Fellowship in 2002 and has career-long commitments to training and clinical trials. He is the recent exPresident of The Association of Breast Surgery (ABS) and is Chair of the National Cancer Intelligence Network (NCIN) Breast Group.

Dr. Wolfgang Janni is currently full professor and director of the Department Obstetrics and Gynecology of the University of Ulm, Germany. He has been appointed to this position in October 2012, after working as full professor and director of the Department Obstetrics and Gynecology of the Heinrich-Heine-University Duesseldorf, Germany, from 2008 until 2012. He received the credentials for professorship at Munich University in 2015, but decided to stay in Ulm.
Following several internships in major medical institutions, including the Yale University, the University of Michigan and New York University, Doctor Janni received his medical training at the LMU-University in Munich. He is board certified gynaecologist, with board certified subspecialities in gynaecological oncology and breast cancer, as well as perinatal medicine. Doctor Janni was appointed Junior Professor of the Department for Gynaecology and Obstetrics of the General Hospital of the Ludwig-Maximilians-University, Munich, in June 2003.
Doctor Janni’s two main fields of research include the relevance of the detection of disseminated tumor cells in the bone marrow of breast cancer patients, and also clinical research. He developed the protocol for the ADEBAR-Study and was principal investigator of the SUCCESS-A/B/C-Trials, clinical phase III studies comprising more than 10,000 primary breast cancer patients with extensive translational research programs. Doctor Janni is currently sponsoring two phase III trials (Detect III – V) in metastatic breast cancer
His research received numerous international awards, including those of ASCO, AACR and SABCS. He is author and co-author of 213 publications in peer-reviewed journals, including the NEJM, JCO and CANCER, and is member of several editorial boards of reknown peer reviewed journals

Prof. Stephen Johnston is Professor of Breast Cancer Medicine and Consultant Medical Oncologist at the Royal Marsden NHS Foundation Trust & Institute of Cancer Research, London. He was the first Director of the UK’s National Institute for Health Research (NIHR) Biomedical Research Centre for Cancer at the Royal Marsden. He graduated in 1983 from Trinity College at The University of Cambridge, and in 1986 from The Medical School at The University of Newcastle upon Tyne. He trained in General Medicine at St Bartholomew’s Hospital and Hammersmith Hospital in London, and subsequently in Medical Oncology at the Royal Marsden Hospital. He gained his PhD from the Institute of Cancer Research at the University of London, and took up his current position as Medical Oncologist on the Breast Unit at the Royal Marsden Hospital in 1997. He has a specialist interest in the treatment of metastatic breast cancer, and his major research interests lie in understanding mechanisms of endocrine resistance in breast cancer. He is actively involved in facilitating the interface between basic and applied research, and is chief investigator of several phase II / III trials of novel therapeutic approaches in advanced disease, including new endocrine therapies and targeted signal transduction inhibitors. He has published over 230 breast cancer related articles in peer-reviewed journals, and is a regular invited lecturer at national & international meetings. He is a member of several scientific committees and advisory boards, a Faculty Member at the American Society for Clinical Oncology, the Deputy-Editor of the international journal ‘Breast Cancer Research’, and a former Trustee of the UK charity ‘Breast Cancer Campaign’ having also been Chairman of their Scientific Advisory Board.

Dr Catherine M. Kelly is a Medical Oncologist at the Mater Misericordiae University Hospital, Dublin. She is Chair of the All Ireland Cooperative Oncology Research Group (ICORG) Breast Cancer Group. Dr Kelly completed Medical Oncology Specialist Training in Ireland and has fellowships from the Odette Cancer Center, Sunnybrook, Toronto, and MD Anderson Cancer Center, Houston, Texas were she was the Susan G. Komen Breast Cancer Fellow. Dr Kelly’s peer reviewed publications have focussed on breast cancer genomics and clinical trial design.

Prof. Michael Kerin is the Chair of Surgery and Vice Dean of Medicine at NUI Galway. As Consultant Surgeon he has a special interest in breast cancer and endocrine surgery. Professor Kerin is the Director of the Lambe Institute for Translational Research, Research Director of Breast Cancer Research, a principal investigator on the BREAST-PREDICT project and co-investigator of numerous other cancer research initiatives. His research interests include molecular profiling in cancer, population genetics and cellular interactions in the cancer microenvironment.

Prof. Elgene Lim is a clinician scientist, NBCF/VCA Practitioner Fellow and Group Leader of the Translational Breast Cancer Research Laboratory at the Olivia Newton John Cancer Research Institute (ONJCRI). He received his MBBS (Melbourne University) in 1995, FRACP (Royal Australasian College of Physicians) in 2006, and PhD (Melbourne University/WEHI) in 2010, where he characterised the human mammary epithelial cell hierarchy and its relation to breast cancer. At the Dana-Farber Cancer Institute (DFCI) in Boston, he progressed from a clinical fellow (2010), postdoctoral fellow (2011), to Instructor in Medicine at the Harvard Medical School (2012-current). He was recruited in 2014 to start a breast cancer laboratory and lead the translational research in breast cancer at the Olivia Newton-John Cancer & Wellness Centre/Austin Health. His laboratory focuses on steroid hormone receptor signalling, including androgen receptor and resistance to endocrine therapies. He also has a long track record of collaboration with national and internal colleagues, especially in the area of preclinical evaluation of novel therapies and biomarkers in breast cancer, and in establishing and utilizing patient derived xenografts for this purpose

Antonio Llombart Cussac MD, PhD is Chairman of the Medical Oncology Service at the University Hospital Arnau de Vilanova in Valencia, Spain and Associate Professor in the Catholic University of Valencia
He received his medical school training in Pamplona and Valencia (from 1982 to 1989). He did his training in medical oncology at the University Hospital in Valencia (form 1999 to 1993). After that, he performed a 4 year fellowship (1994 to 1997) in the Breast Cancer Unit at Institute Gustave Roussy (Villejuif, France) focusing on new drugs (phase I and II studies); becoming a medical staff member from 1995 to 1997. From 1997 to 2005 he was attached to the Department of Medical Oncology at the Instituto Valenciano de Oncologia. In 2003 was promoted to the Head of the Breast Cancer Research Unit.
Between September 2005 to August 2010, he has led the Medical Oncology Service at the University Hospital Arnau de Vilanova in Lleida, Spain. He obtained is PhD degree in Breast Cancer in 2005. Since 2010, he is coordinating a clinical unit integrated by pharmacologists, surgeons, pathologists and biologists from several centers working with cytotoxic and molecular agents both in human and animal models. His major present focus is on translational clinical trials and correlative science in the preoperative management of breast and endometrial cancer patients.
Dr. Llombart is the President and Co-founder of the company Medica Scientia Innovation Research (MedSIR ARO), an academic research organization focused in the scientific knowledge activity and clinical research development (www.medsir.org). This company conducts the independent clinical trials created by own Scientific Committee – MERIBEL trial (Eribulin first line MBC), TRASTYVERE study, POEM (temsirolimus in endometrial carcinoma, etc…) – and clinical trials in collaboration with pharmaceutical companies or international cooperative groups (NSABP-FB7, Phase I TDM1, POLEN trial, NABUCO trial), focused on oncology setting.
He is actively involved in many international co-operative groups and trials. He is principal investigator in NEO-PARP (NCT01204125) trial, PAMELA trial (Molecular signature trastuzumab + Lapatinib), VICTORIA Study (Vinflunine phase III first line) and GEICAM/2009-02 (NCT01298193). Since 2012, he is president in SOLTI breast cancer group.
Antonio Llombart develops a consultant activity in Oncology area and breast cancer for several pharmaceutical companies: Eli Lilly and company (USA), Novartis pharmaceutical, Pfizer Oncology Spain and Boehringer Ingelheim. He is member of International Scientific Committee for P024 study (letrozol in neoadjuvant treatment), for ZO-FAST study and International expert of the clinical investigation committee for breast cancer (local and advanced). Institut National du Cancer (INCA), Paris, France (2005 a 2007).
He is author of more than 80 publications (see below the last 3 years) and he is member of Editorial Board of the journal “Oncologia, La revue francophone de formation en oncologia” since 2004 and Board Member of Sociedad Española de Oncología Médica (2005 a 2009)

Prof. Bruce Mann is Professor of Surgery at the University of Melbourne and Director of The Breast Service at the Royal Melbourne and Royal Women’s Hospital in Melbourne. He is on the council of Breast SurgANZ, the Scientific Advisory Committee of the ANZ Breast Cancer Trials Group and is past president of the Clinical Oncology Society of Australia. He has been involved in many clinical trials and much clinical and translational research regarding breast cancer, with his main research interest being tailoring treatment to the disease and the patient.

Dr. Stacy Moulder completed her fellowship in Hematology/Oncology at the Vanderbilt-Ingram Cancer Center, where she also obtained a Masters of Science in Clinical Investigation. She is a medical oncologist who exclusively sees breast cancer patients and has been appointed within the Breast Medical Oncology program for 10 years at MD Anderson Cancer Center, most recently as the Chief of the Section of Clinical Research. Through this appointment, she maintains a research interest in drug development with novel targeted therapies for the treatment of triple negative breast cancer, predominately as targeted therapy trials for the treatment of metastatic breast cancer or neoadjuvant trials in patients with localized, chemotherapy insensitive disease. Her research interests are focused on the mesenchymal subtype of TNBC, which includes metaplastic breast cancer, a particularly aggressive, chemotherapy refractory form of TNBC that has a high frequency of aberrations in PI3K/Akt/mTOR pathway and has demonstrated response to mTOR inhibition in combination with chemotherapy.

Dr. Seigo Nakamura gained his medical degree in 1982 from Chiba University. He started his career as general surgeon at St. Luke’s International Hospital in Tokyo, Japan after graduation. After 28-years service at St.Luke’s International Hospital, he has moved to Showa University School of Medicine. Currently, Dr. Nakamura is Professor and Chairman, Department of Surgery, Division of Breast Surgical Oncology and Director, Breast Center of Showa University Hospital. He is also Chairman of the Board of Directors in the Japanese Breast Cancer Society. He has dedicated himself to clinical practice and clinical trials on breast cancer. Dr. Nakamura has focused on genetic diagnosis and tailor treatment.

Prof. Sarah Pinder is Chair of Breast Pathology at Kings College London. She is the Lead Specialist Breast Pathologist at Guy’s & St Thomas’ Hospitals and has a large referral practice in addition to the ‘routine’ NHS histopathology workload. Her translational research interests are also focused on breast cancer pathology (particularly DCIS) and she has published over 250 articles in the peer-reviewed literature.
She Chairs the UK NHS Breast Screening Pathology Coordinating Committee, is a member of the NCIN Breast Reference Group, the Translational Sub-group of the NCRI Breast CSG and the Sloane Project (National UK DCIS audit) Steering Group and is an Expert Adviser for the NICE Centre for Clinical Practice. She is also member of various clinical trial and translational research committees including the low risk DCIS trial (LORIS), OPTIMA and OPPORTUNE, amongst others.

Philip Poortmans MD PhD
In 1986 Philip Poortmans MD PhD completed his medical studies at the University of Antwerp. He was trained as a radiation oncologist at the Middelheim and Vincentius Hospitals in Antwerp under the supervision of Van den Bogaert c.s.
In 1991 he started as a radiation oncologist in Tilburg. Since August 2014 he chairs the department of radiation oncology of the Radboud University Medical Centre, Nijmegen.
Special interests: breast cancer, quality assurance in clinical trials, malignant lymphoma and rare tumours.
In 2005: PhD thesis on quality assurance in clinical trials in breast cancer at the University of Maastricht.
Since 1992 active in the EORTC, currently member of the Radiation Oncology (secretary 2006-2015), Lymphoma and Breast Groups; Quality Assurance Committee of the EORTC (2003-2015).
2005 – 2008: councillor of the board of ESTRO.
2007 – 2010: representative for radiation oncology in the Multidisciplinary Oncology Committee of ESMO.
2013: president-elect and, from 2014-2016, president of ESTRO.
ESTRO School of Radiotherapy and Oncology:
– Course director of the teaching courses “Multidisciplinary Management of Breast Cancer” and “Accelerated Partial Breast Irradiation”;
– Liaison person for all multidisciplinary courses;
– Core member of the Educational and Teaching Committee.
2012: “Technical Basis of Radiation Therapy. Practical Clinical Implications (Springer); co-edited with Levitt, Purdy and Perez.
Honorary membership of BVRO/ABRO since 2012, of ESSO since 2014 and of SEOR since 2015.
2011 and 2012 nominated as “Toparts” (Outstanding doctor) by the Dutch radiation oncologists.

Dr. Alistair Ring is a consultant in medical oncology at the Royal Marsden Hospital. He trained at the Royal Marsden, St George’s and Guy’s Hospitals, London, and gained his MD research degree in 2005 from the Institute of Cancer Research at the University of London. In 2008 he was appointed as Senior Lecturer in Oncology at Brighton and Sussex Medical School, where he was Director of the Brighton NIHR Clinical Research Facility. In 2014 he was appointed Consultant in Medical Oncology at the Royal Marsden Hospital, where is a chair of the Committee for Clinical Research. He is a member of the National Cancer Research Institute (NCRI) Breast Clinical Studies Group, and chair of the NCRI Advanced Breast Cancer subgroup, which oversees trials for advanced breast cancer in the UK.

Dr. Cesar A. Rodriguez
• Medical Oncologist & Associate Professor.
Department of Medical Oncology. Breast Cancer Unit.
University Hospital. Salamanca. Spain.
• Member of the Executive Board of the Spanish Society of Medical Oncology
• Editor or Co-editor of 13 textbooks of Oncology.
• Author of more than 50 chapters in medical textbooks.
• Author or Co-author of about 90 scientific papers in national and international journals with special interest in breast cancer and supportive treatment.
• Author or Co-author of more than 250 proceedings in national and international meetings.
• Invited speaker in more than 125 meetings and symposia.
• Director and Co-director of several national programs of training for medical professionals in Breast Cancer and Supportive Care in Cancer Patients.

Dr. Isabel Rubio is the Chief of Breast Surgical Oncology at the Hospital Universitario Vall d´Hebron, Barcelona and Associate Professor of Surgery at the Universitat Autònoma, Barcelona. She trained as a Breast Surgical Oncology Fellow at The University of Arkansas for Medical Sciences at Little Rock and at the MD Anderson Cancer Center in Houston.
Dr. Rubio is the President of the Spanish Association of Breast Surgeons (AECIMA) and a reviewer in the Breast Section of the Journal of Surgical Oncology, The Breast and the European Journal of Surgical Oncology. She joined the ESSO Education and Training Committee in 2013 and the SSO Outreach Committee in 2014. She is also officer of the Division of Breast Surgery at the European Union of Medical Specialists (UEMS) and examiner at the European Board for Breast Surgery.
Dr. Rubio has published national and international peer review manuscripts and collaborated in book chapters. Her interest is in sentinel lymph node biopsy, neoadjuvant treatments, ultrasound guided surgery and surgical management of BRCA mutation carriers.

Prof. Peter Schmid was appointed as Chair in Cancer Medicine at Barts Cancer Institute, Queen Mary University London, in 2013. He is Director of the Breast Cancer Programme at the St. Bartholomew Cancer Centre and Lead of the Centre of Experimental Cancer Medicine at Barts Cancer Institute. Professor Schmid also leads the academic breast cancer programme and the cancer immune therapy group at Barts Cancer Institute and is Lead of the Barts/Brighton Experimental Cancer Medicine Centre.
Professor Schmid trained in medicine at Ludwig-Maximilians-University Munich, Technical University of Munich and University of Aberdeen. He was awarded scholarships by the ‘Studienstiftung des deutschen Volkes’, the ‘Hanns-Seidel-Foundation’, and the ‘Deutscher Akademischer Austauschdienst’. Professor Schmid completed a MD on mitochondrial creatine kinase at the Technical University Munich. He subsequently trained at the University Hospital Charité in Berlin in internal medicine, haematology and oncology, where he became head of breast cancer research and the phase I programme. He completed his PhD at the Charité University in Berlin in 2005 and was awarded the “habilitation and venia legendi” and an external readership by the Charité University in 2006. From 2005-2010, Prof. Schmid was a Senior Clinical Lecturer and Director of the Hammersmith Early Clinical Trials Unit at Imperial College London. In 2010, he was appointed as Foundation Chair in Cancer Medicine at the University of Sussex, and he was Director of the Clinical Investigation and Research Unit at Brighton and Sussex University Hospitals until his move to Barts.
Professor Schmid’s specialist cancer interests are breast cancer, cancer immune therapy and early drug development. His research interests lie in stratified cancer medicine utilising novel biomarkers and innovative, biomarker-driven clinical trial strategies to develop new treatment strategies. Professor Schmid has successfully led more than 20 national/international academic clinical studies, ranging from phase I to III, and several translational research programmes. He leads a collaborative group to establish circulating tumour DNA as a biomarker and is principal investigator of 2 ongoing, prospective international biomarker studies on predictive epigenetics from circulating tumour DNA.
Professor Schmid is a member of several national and international cancer organizations and research groups and has been involved in international consensus meetings on the management of breast cancer. Professor Schmid is a member of ESMO breast cancer Faculty, the UK NCRN breast cancer study group and of the breast cancer and translational research steering groups of the German cooperative group of medical oncology. He has authored or –co-authored 145 publications and has published a book on the management of bone metastases (3rd edition).

Dr. Benjamin Smith is a radiation oncologist specializing in breast cancer and health services research at The University of Texas MD Anderson Cancer Center. He leads the breast radiation oncology research group at MD Anderson. He is also the vice-Chair of the ASTRO Clinical Affairs and Quality Committee and has led ASTRO guidelines on partial breast and whole breast irradiation. His current research focuses on studying the long-term effects of local therapy on quality of life, patient satisfaction, and cost of care.

Dr. Christos Sotiriou is the head of the Breast Cancer Translational Research Laboratory J-C Heuson at the Université Libre de Bruxelles located at the Jules Bordet Institute. He is Advisory Council Member of the Susan G. Komen for the Cure and recently Associate Editor (Breast Tumors) of “Annals of Oncology”. Internationally renowned translational researcher, author and co-author of over 200 peer-reviewed articles, Dr. Sotiriou’s research is focused on genomics in breast cancer.

Dr. Salomon Stemmer completed his medical education at the faculty of medicine, Ben Gurion University, Israel, was trained by Dr. James Holland at Mt. Sinai, New York, worked several years at the University of Colorado Health Sciences Center. An expert in Cancer Therapy and Palliative Care medicine, Dr. Stemmer is the Head of the Research Unit of the Division of Oncology, Davidoff Center, Rabin Medical Center, affiliated to the Sackler School of Medicine (Associate Clinical Professor) Tel Aviv University, Israel. He serves as the deputy head of the IRB committee, the ethic committee and end of life committee.
Dr. Stemmer is leading translational research efforts in cancer therapy (Phase I-II-III trials) and research regarding treatment related toxicity. He is an expert in the bench to bedside and vice versa research. In the last few years his main laboratory research includes patient derived xenograft for several malignancies and the incorporation of patient’s own immune system to the mouse harboring his self-tumor (Trimera PDX).
Dr. Stemmer believes in treating the patient as a whole: deals with the complexity of the patient with a malignant process, using novel approaches based upon precise medicine, PDX models taking into account tolerability of treatment, and also emphasizing risk-benefit ratio and quality of life.
Dr. Stemmer advises to pharmaceutical and start-up companies in the development of new anti-cancer agents, delivery methods etc. He has published over 80 peer reviewed papers in leading oncology and science journals.

Mr. Ash Subramanian qualified from Guy’s and St Thomas’ Hospitals in 1997 with triple honours and a first class Bachelor’s degree in immunology. He then completed his surgical training mainly in London and Surrey including a highly competitive National Oncoplastic Fellowship before being appointed a Consultant Oncoplastic Surgeon in 2011. He has published extensively and also presented his work both nationally and internationally. His current research interests are patient choice following mastectomy and reconstruction in the elderly. He is currently an Honorary Lecturer at Brighton University Medical School, Royal College of Surgeons Tutor at East Sussex Healthcare NHS Trust and Director of Communications for the Association of Breast Surgeons of Great Britain and Ireland.

Prof. Marc W. Sutterlin is full Professor for Obstetrics & Gynecology, Medical Director and Chairman of the Department of Obstetrics & Gynecology and the Interdisciplinary Breast Cancer Center of the University Medical Center Mannheim/Germany.After extensive training in all subspecialties of Obstetrics & Gynecology in the University Hospitals of Hannover, London and Würzburg, he focused his clinical and scientific interest on gynaecologic oncology and breast cancer treatment. He has more than 10 years of experience with intraoperative radiotherapy.

Prof. Alastair Thompson graduated from the University of Edinburgh, UK with Distinction in Surgery and subsequently trained as a Clinician Scientist and Fellow of the Royal College of Surgeons of Edinburgh. In 2014 he moved from the position of Professor of Surgical Oncology, Clinical Lead for the Dundee Cancer Centre/Experimental Cancer Medicine Centre and Foundation Director of the Clinical Research Centre, Dundee, UK to the Department of Surgical Oncology, The University of Texas, MD Anderson Cancer Center in Houston, Texas, specializing in breast cancer.
Achievements to date include setting up and chairing the Breast Cancer Campaign Breast Tissue Bank Board for the UK and Eire, leading the 12,000 patient UK National Audit of Screen Detected DCIS and, for 5 years to 2014, chairing the UK National Cancer Research Institute, Breast Clinical Studies Group (with oversight of 120 academic and commercial clinical studies in breast cancer). He actively contributes to a range of clinical trials in the prevention, early detection and therapy of breast cancer. He remains as UK Chief Investigator for a number of key trials including MINDACT, MA32 and SOLE and continues to chair the data monitoring committees and trials steering groups for several phase II drug trials and phase III surgical trials respectively in the UK.
Active in translational laboratory research, he built a breast cancer research program over 15 years in Dundee, including a xenograft program and tissue banking facility with a focus on the p53 network and drug development. He has successfully supervised 20 PhD or research MD students and currently has 4 students completing PhDs. The impact of over 200 peer reviewed research papers has included global firsts demonstrating the effect of drugs in vivo in animal models and in human cancers.
He continues to provide leadership in trials and clinical translational research with colleagues in Europe and Australasia while establishing clinical trials and laboratory collaborations in the US, through membership of the American Society of Clinical Oncology, American Association of Cancer Research, South West Oncology Group and Translational Breast Cancer Research Consortium.

Dr. Sunil Verma is a Professor and Head of the Department of Oncology at the University of Calgary. He is also the Medical Director of the Tom Baker Cancer Centre. He completed his medical degree and postgraduate training in internal medicine and medical oncology at the University of Alberta in Canada. Dr. Verma also completed a fellowship in breast cancer at the University of Toronto and a Masters degree in Medical Education at the University of Southern California.
Dr. Verma is internationally recognized for his research and education leadership in breast cancer. His research interests include developing novel therapies for breast cancer, reducing toxicities associated with systemic treatment and medical education. He is the principal investigator for many trials in breast cancer including a number of practice changing Phase III trials in breast cancer. His work has been published in the New England Journal of Medicine, The Lancet, Journal of Clinical Oncology and Cancer. He has led and created numerous innovative educational projects in oncology and has won several teaching and mentoring awards.

Dr. Sarah Vinnicombe is a Clinical Senior Lecturer in Cancer Imaging and Consultant Radiologist at Ninewells Hospital Medical School, University of Dundee, a post she took up in 2011. Having completed her radiological training with distinction at St. George’s Hospital, University of London, she was appointed as a consultant radiologist at St Bartholomew’s Hospital Medical School, where she was the Lead in Haematologic Oncology Imaging, Lead in Breast Imaging and Director of Breast Screening for East London and the City. During her time at Bart’s she developed and ran the breast MRI service and set up a highly successful subspecialty training programme in Breast Radiology.
She has a longstanding interest in all aspects of breast imaging and in cross-sectional oncological imaging, particularly of lymphoma. She lectures and teaches widely, particularly on breast MRI and imaging aspects of breast cancer risk, both nationally and internationally. Her main research interests are in the evaluation of breast density, personalised breast cancer screening and in early evaluation and prediction of response to neoadjuvant chemotherapy with MRI and ultrasound.
In 2013, Dr Vinnicombe was the British Society of Breast Radiologists’ Visiting Professor and she is an elected fellow of the International Cancer Imaging Society.

Stefano Zurrida obtained his degree in Medicine and Surgery (cum laude) in 1986 and soon after began working at the National Cancer Institute of Milan. He obtained specialization in General Oncology and General Surgery from the University of Pavia in 1989 and 1994, respectively, and a specialization in Hygiene and Preventive Medicine from the University of Verona in 2000. In 1994, he became Vice Medical Officer of that Institute. He was Executive Advisor to the Scientific Director and co-Director of the Division of Senology.
Stefano Zurrida was appointed Associate Professor of General Surgery at the University of Milan, and has been a contract lecturer at the Specialization School of Oncological Surgery, University of Varese since 2015. He has for some time acted on behalf of the Italian Ministries of health and Foreign Affairs, with specific commissions in areas concerned with developing international collaboration in healthcare, drawing up guidelines in early disease detection programmes in cancer treatment, and health organization. From 2000 to 2001, he was Executive Secretary to the Italian Health Minister (then Professor Umeberto Veronesi). In 2013, he was appointed Senior Honorary Fellow at International Prevention Research Institute of Lyon.